Incidence of acute urinary retention in patients with prostatic adenoma and 8-year long tamsulosin therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This report introduces results of an 8-year study estimating the risk of acute urinary retention in patients with stage I prostatic adenoma. Patients were randomly assigned into two groups. The first group consisted of 331 men was regularly taking Omnic (tamsulosin) 0.4 mg 1 time daily for 8 years as a means of medical therapy. The second group consisted of 334 patients treated with herbal preparations (Gentos, Tadenan or Speman). In the case of acute urinary retention patients were taken to the urological department to release urine from the urinary bladder by catheterization or by the surgical procedure. The incidence of acute urinary retention in group 1 ranged from 0.3 to 1.2% per year and, for a total of 8 years of follow-up was 6.45%. In the second group, it ranged from 1.8 to 7.3% per year, making a total of 36.2%. Therefore, the risk of acute urinary retention in patients receiving Omnic (tamsulosin) was reduced by 5.6 times in comparison with the group of patients treated with herbal medications. Thus, the need for surgery decreased from 27.8 to 6.3%. According to the results of an 8-year long tamsulosin was found as a safe and highly effective means to reduce the risk of acute urinary retention.

Full Text

Restricted Access

About the authors

M. I Davidov

SBEI HPE «Perm State Medical Academy n.a. ac. E.I. Vagner»

Email: midavidov@maiI.ru

K. L Lokshin

Research Institute of Uronephrology and Human Reproductive Health of Sechenov First Moscow State Medical University

I. S Gorbunova

SBEI HPE «Perm State Medical Academy n.a. ac. E.I. Vagner»

References

  1. Emberton M., Andriole G.L., Rosette J., Djavan B., Hoefner K., Vela Navarrete R., Nordling J., Roehrborn C., Schulman C., Teillac P., Tubaro A., Nickel J.C. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61:267-273.
  2. Горюнов В.Г., Давидов М.И. Острая задержка мочеиспускания. Урол. и нефрол. 1994;4:44-48.
  3. Аляев Ю.Г., Винаров А.З., Газимиев М.А., Мельников А.В. Адреноблокаторы в профилактике острой задержки мочеиспускания после оперативных вмешательств. Хирургия. 1999;12:43-45.
  4. Давидов М.И. Предрасполагающие факторы к возникновению острой задержки мочеиспускания при аденоме предстательной железы. Урология. 2007;2:25-31.
  5. Сергиенко Н.Ф., Васильченко М.И., Бегаев А.И., Щекочихин А.В., Шершнев С.П., Потоцкий М.М., Рейнюк О.Л. Острая задержка мочеиспускания при аденоме предстательной железы. Урология. 2010;4:61-63.
  6. Emberton M., Anson K. Acute urinary retention in men. Br. Med. J. 1999;318(3):921-925.
  7. Трапезникова М.Ф., Морозов А.П., Поздняков К.В. Острая задержка мочеиспускания при аденоме предстательной железы. Урология. 2007;3:98-102.
  8. Неймарк А.И., Ноздрачев Н.А. Опыт применения силодозина при острой задержке мочеиспускания, вызванной аденомой предстательной железы. Урология. 2013;4:47-51.
  9. Boyle P., Robertson C., Wilson T., D’Omofrio A., Benichou J. Risk factors for acute urinary retention in men with benign prostatic hyperplasia. In.: Abstracts from the XVinth Congress of the EAU. March 12-15, 2003. Madrid: Spam. Madrid; 2003. P. 94.
  10. Hartung R. Do alpha-blokers prevent the occurrence of acute urinary retention? Eur. Urol. 2001;39(6):13-18.
  11. Verhamme K., Van Wijk M., Van Der Lei J. et al. Incidence of acute urinary retenti on in the general male population and in men with benign prostatic hyperplasia. In.: Abstracts from the XlXth Congress of the EAU. March 24-27, 2004. Vienna; 2004. P. 146.
  12. Пушкарь Д.Ю., Раснер П.И. Современный алгоритм обследования и лечения больных аденомой предстательной железы. Урология. 2007;3:87-94.
  13. Marberger M.J., Andersen J.T., Nickel J.C., Malice M.P., Gabriel M., Pappas F, Meehan A., Stoner E., Waldstreicher J. Prostate Volume and Serum Prostate-Specific Antigen as Predictors of Acute Urinary Retention. Eur. Urol. 2010;38:563-568.
  14. Manikandan R., Srirangam S., O’Reily P, et al. Management of acute urinary retenti on to benign prostatic hyperplasia. Br. J. Urol. Int. 2004;93(1):84-88.
  15. Kim H., Kim. J., Benson D., Bales G.T., Gerber G.S. Results of treatment with tamsulosin in men with acute urinary retention. Tech. Urol. 2001;7(4):256-260.
  16. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ Statistica. M.: Медиа Сфера, 2003.
  17. McConnel J.D., Roehrborn C.G., Bautista O.M. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003;349(25):2387-2398.
  18. Roehrborn C.G., Siami P., Barkin J., Damiao R., Major-Walker K., Nandy I., Morrill B.B., Gagnier R.P., Montorsi F.; CombAT Study Group. The effect of combination therapy with du tasteride and tamsulosin on clinical outcomes in men with symptomatic benign pros - tatic hyperplasia: 4 - year results from the CombAT study. Eur. Urol. 2010;57(1):123-131.
  19. Аполихин О.И., Сивков А.В., Бешлиев Д.А., Абдуллин И.И. Современные возможности медикаментозного лечения аденомы предстательной железы. Урология. 2010;2:54-59.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media